SIM
TGTX icon

Spark Investment Management’s TG Therapeutics TGTX Stock Holding History

Spark Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-54,400
Closed -$305K – 578
2019
Q3 		$305K Hold
54,400
– – 0.04% 292
2019
Q2 		$470K Buy
+54,400
New +$411K 0.03% 379

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Spark Investment Management's TGTX Position: Q4 2019 in Review

Spark Investment Management sold out of TG Therapeutics (TGTX) in Q4 2019, closing a stake of 54,400 shares — an estimated $305K sold.

Spark Investment Management first reported a position in TGTX in Q2 2019 and held it in 2 quarters. The position peaked at $470K in Q2 2019. 135 funds tracked by Wall St. Rank hold TGTX as of Q4 2019.

  • Spark Investment Management reported no remaining TG Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Spark Investment Management sold 54,400 TG Therapeutics shares in Q4 2019, an estimated $305K.
  • Spark Investment Management first reported a position in TG Therapeutics in Q2 2019 and held it in 2 quarters.
  • Spark Investment Management's TG Therapeutics position peaked at $470K in Q2 2019.
  • 135 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2019.

Based on Spark Investment Management's 13F filing for Q4 2019, filed 11 Feb 2020.